Development, Commercialization and Supply Agreements (Tables)

9 Months Ended

Sep. 30, 2025

License And Collaboration Agreements [Line Items]

Summary of Licensing Revenue

In thousands	Amount
Licensing revenue recognized during the nine months ended September 30, 2025 (1)	$	—
Licensing revenue recognized during the nine months ended September 30, 2024 (1)		19,450
Licensing revenue recognized from contract inception through both September 30, 2025 and December 31, 2024	$	40,081

(1)Licensing revenue under the DCS Agreement is recognized concurrent with the input measure of support hours provided by the Company to Edding in achieving the combined development and regulatory performance obligation, which in the Company’s judgment is the best measure of progress towards satisfying this performance obligation.

Summary of Product Approval

The Company received approval of VASCEPA under the MARINE and REDUCE-IT indications in the following countries:

Country	MARINE	REDUCE-IT	Launch Date
Lebanon	March 2018	August 2021	June 2018
United Arab Emirates	July 2018	October 2021	February 2019
Qatar	December 2019	April 2021	May 2022
Bahrain	April 2021	April 2022	September 2023
Kuwait	December 2021	March 2023	September 2023
Saudi Arabia	March 2022	June 2023	September 2023

Summary of Reimbursement

Country	Individual Reimbursement	National Reimbursement	Product Availability	Launch Date
Sweden	–	March 2022	March 2022	March 2022
Finland	–	October 2022	December 2022	December 2022
England/Wales	–	July 2022	October 2022	October 2022
Spain	–	July 2023	September 2023	September 2023
Netherlands	–	August 2023	September 2023	September 2023
Scotland	–	August 2023	August 2023	September 2023
Greece (1)	–	May 2024	June 2024	June 2024
Portugal	–	August 2024	August 2024	September 2024
Italy	–	December 2024	December 2024	January 2025
Slovenia (2)	–	September 2025	October 2025	October 2025
Austria	September 2022	February 2025	September 2022	–
Denmark	June 2022	–	June 2022	–

(1) Vianex will be the sole and exclusive distributor of VAZKEPA in the Greek territory to import, register, distribute and commercialize VAZKEPA.

(2) Salus will be the sole and exclusive distributor of VAZKEPA in the Slovenian territory to import, register, distribute and commercialize VAZKEPA.

Changes in Balances of Contract Assets and Liabilities and Revenues Recognized

The following table presents changes in the balances of the Company’s contract assets and liabilities during the nine months ended September 30, 2025 and 2024:

In thousands	Balance at Beginning of Period		Additions		Deductions			Balance at End of Period
Nine months ended September 30, 2025:
Contract assets	$	—	$	—	$	—		$	—
Contract liabilities:
Deferred revenue	$	—	$	—	$	—		$	—
Nine months ended September 30, 2024:
Contract assets	$	—	$	—	$	—		$	—
Contract liabilities:
Deferred revenue (1)	$	4,850	$	—	$	(4,850	)	$	—

(1)The approximately $4.9 million reduction consists primarily of recognition of $4.0 million relating to the change in estimate for Edding during the three months ended June 30, 2024.

During the nine months ended September 30, 2025 and 2024, the Company recognized the following revenues as a result of changes in the contract asset and contract liability balances in the respective periods:

In thousands	Nine months ended September 30,
Revenue recognized in the period from:	2025		2024
Amounts included in contract liability at the beginning of the period	$	—	$	1,180
Performance obligations satisfied in previous periods	$	—	$	3,670

Edding

License And Collaboration Agreements [Line Items]

Summary of Transaction Price Comprising Upfront Payments and Milestones

The transaction price is comprised of the following upfront payments and milestones:

In thousands
Transaction Price Components	Achieved	Amount
Upfront fee	February 2015	$	15,000
Submission of the CTA for the MARINE indication	March 2016		1,000
Approval of VASCEPA under the MARINE indication	March 2017		5,000
Submission of the CTA for the REDUCE-IT indication	October 2023		3,000
Approval of VASCEPA under the REDUCE-IT indication	June 2024		15,000
Regulatory Development Support	Various		1,081
Total Transaction Price		$	40,081

HLS

License And Collaboration Agreements [Line Items]

Summary of Transaction Price Comprising Upfront Payments and Milestones

The transaction price is comprised of the following upfront payments and milestones:

In thousands
Transaction Price Components	Achieved	Amount
Upfront fee	September 2017	$	5,000
Achievement of the REDUCE-IT trial primary endpoint	September 2018		2,500
Approval from Health Canada	December 2019		2,500
Regulatory exclusivity from the Office of Patented Medicines and Liaison	January 2020		3,800
Total Transaction Price		$	13,800